Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Jonathan C. JavittChairman and Chief Scientist | NRX PharmaceuticalsNRXP | Open-market buy | 24/12/17 | 24/12/18 | 40,000 sh | $1.17 | $46,800 | +89.6% |
Chaim HurvitzDirector | NRX PharmaceuticalsNRXP | Open-market buy | 23/08/30 | 23/09/11 | 70,000 sh | $0.29 | $20,300 | +14.0% |
Aaron GorovitzDirector | NRX PharmaceuticalsNRXP | Open-market buy | 23/08/30 | 23/09/11 | 35,000 sh | $0.32 | $11,200 | +50.0% |
Jonathan C. JavittChief Scientist | NRX PharmaceuticalsNRXP | Open-market buy | 23/08/23 | 23/08/24 | 100,000 sh | $0.33 | $33,000 | +28.9% |
Jonathan C. JavittChief Scientist | NRX PharmaceuticalsNRXP | Open-market buy | 23/08/22 | 23/08/23 | 200,000 sh | $0.32 | $64,000 | +136.7% |